핵의학 시장 보고서 : 동향, 예측 및 경쟁 분석(-2035년)

The future of the global nuclear medicine market looks promising with opportunities in the oncology, thyroid, and cardiology markets. The global nuclear medicine market is expected to reach an estimated $15 billion by 2035 with a CAGR of 7.4% from 2026 to 2035. The major drivers for this market are the increasing use of targeted therapies, the rising adoption of early diagnosis methods, and the growing demand for personalized treatment options.

• Lucintel forecasts that, within the type category, therapeutic nuclear medicine is expected to witness higher growth over the forecast period.
• Within the application category, oncology is expected to witness the highest growth.
• In terms of region, APAC is expected to witness the highest growth over the forecast period.

Emerging Trends in the Nuclear Medicine Market

The nuclear medicine market is experiencing rapid evolution driven by technological advancements, increasing demand for personalized healthcare, and a growing focus on early diagnosis and treatment of various diseases. As healthcare providers seek more effective and less invasive options, the market is witnessing significant innovations in imaging techniques, radiopharmaceuticals, and treatment protocols. These developments are not only enhancing diagnostic accuracy but also expanding the scope of nuclear medicine applications across different medical fields. The following key trends highlight the transformative changes shaping this dynamic industry and their implications for stakeholders.

• Technological Advancements in Imaging: The integration of hybrid imaging systems like PET/CT and PET/MRI is revolutionizing diagnostic capabilities. These advanced tools provide higher resolution images, better localization of disease, and improved patient outcomes. As technology becomes more sophisticated and accessible, healthcare providers can diagnose conditions earlier and with greater precision, leading to more targeted treatments and reduced healthcare costs.
• Growing Use of Personalized Radiopharmaceuticals: The development of tailored radiopharmaceuticals is enabling personalized treatment plans for patients. These specialized compounds target specific disease markers, improving efficacy and minimizing side effects. This trend is particularly impactful in cancer therapy, where precision medicine is transforming patient management and increasing survival rates, thereby expanding the market for customized nuclear medicine solutions.
• Rising Demand for Theragnostic: Theragnostic combines diagnostic imaging and targeted therapy using the same radiopharmaceuticals. This approach allows for real-time monitoring of treatment response and adjustment of therapy as needed. The increasing adoption of theragnostic is driving market growth by offering more effective, patient-specific treatment options, especially in oncology, and fostering innovation in radiopharmaceutical development.
• Regulatory and Reimbursement Changes: Evolving regulatory frameworks and reimbursement policies are influencing market dynamics. Streamlined approval processes and expanded coverage for nuclear medicine procedures are encouraging adoption among healthcare providers. These changes facilitate faster market entry for new products and support broader clinical use, ultimately improving patient access to advanced diagnostic and therapeutic options.
• Expansion into Emerging Markets: Growing healthcare infrastructure and rising awareness of nuclear medicine benefits are fueling market expansion in emerging economies. Investments in training, infrastructure, and regulatory frameworks are enabling these regions to adopt nuclear medicine technologies. This trend broadens the global market reach, diversifies revenue streams, and promotes innovation tailored to diverse healthcare needs.

In summary, these trends are collectively reshaping the nuclear medicine market by enhancing technological capabilities, enabling personalized treatments, expanding clinical applications, and broadening geographic reach. As a result, the industry is poised for sustained growth, improved patient outcomes, and increased integration of nuclear medicine into mainstream healthcare practices.

Recent Developments in the Nuclear Medicine Market

The nuclear medicine market is experiencing rapid advancements driven by technological innovations, increasing clinical applications, and growing demand for personalized healthcare. These developments are transforming diagnostic and therapeutic procedures, expanding market reach, and improving patient outcomes. Stakeholders are investing heavily in research and infrastructure to capitalize on emerging opportunities. As the industry evolves, understanding these key growth areas is essential for strategic planning and investment decisions in this dynamic sector.

• Technology Advancements: Enhanced imaging techniques and radiopharmaceuticals are improving diagnostic accuracy and treatment efficacy. Innovations like hybrid imaging systems (PET/CT, SPECT/CT) enable precise localization of disease, reducing invasive procedures. These advancements are expanding clinical applications, attracting investments, and increasing adoption rates worldwide. The improved safety profiles and shorter procedure times are also boosting patient acceptance, ultimately driving market growth and fostering innovation in product development.
• Increasing Clinical Applications: The scope of nuclear medicine is broadening with new indications such as targeted cancer therapy, cardiology, neurology, and infectious disease management. This diversification is driven by research demonstrating improved outcomes and reduced side effects compared to traditional treatments. As clinical evidence accumulates, healthcare providers are more inclined to adopt nuclear medicine procedures, leading to higher demand for radiopharmaceuticals and equipment. This trend is significantly expanding the market and encouraging new product development.
• Rising Investment and Infrastructure: Governments and private entities are investing heavily in nuclear medicine infrastructure, including manufacturing facilities, research centers, and clinical settings. This investment aims to enhance regional capabilities, especially in emerging markets, and ensure supply chain stability. The expansion of infrastructure supports increased procedure volumes and facilitates the training of healthcare professionals. These developments are crucial for market growth, enabling wider access to nuclear medicine services and fostering innovation in the sector.
• Regulatory Support and Reimbursement Policies: Favorable regulatory frameworks and reimbursement policies are encouraging the adoption of nuclear medicine procedures. Governments are streamlining approval processes for new radiopharmaceuticals and providing coverage for diagnostic and therapeutic applications. This support reduces financial barriers for healthcare providers and patients, accelerating market penetration. Clearer guidelines and reimbursement schemes are also fostering innovation and ensuring sustainable growth in the industry.
• Market Expansion in Emerging Economies: Rapid economic growth and increasing healthcare awareness are driving nuclear medicine adoption in emerging markets. Investments in healthcare infrastructure, rising prevalence of chronic diseases, and government initiatives are expanding access to nuclear medicine services. Local manufacturing and partnerships are reducing costs and improving supply chains. This expansion is opening new revenue streams, diversifying the market, and positioning emerging economies as significant growth hubs for nuclear medicine.

These developments are collectively transforming the nuclear medicine market by enhancing technological capabilities, broadening clinical applications, and expanding infrastructure and access. Increased investments, supportive policies, and market expansion in emerging economies are driving growth and innovation. As a result, the industry is poised for sustained expansion, offering improved diagnostic and therapeutic options and ultimately benefiting patients worldwide. These trends are shaping a more dynamic, accessible, and innovative nuclear medicine landscape.

Strategic Growth Opportunities in the Nuclear Medicine Market

The nuclear medicine market is experiencing rapid growth driven by technological advancements, increasing disease prevalence, and expanding applications in diagnostics and therapy. Rising awareness and regulatory support further bolster market expansion. Strategic investments in research and development are unlocking new treatment options, while collaborations between healthcare providers and industry players enhance accessibility. As personalized medicine gains prominence, nuclear medicine is positioned to play a pivotal role in improving patient outcomes and healthcare efficiency globally.

• Expanding Diagnostic Capabilities Through Advanced Imaging Techniques: Innovations in imaging technology, such as PET and SPECT, are enhancing diagnostic accuracy for cancer, cardiovascular, and neurological diseases. These advancements enable early detection, precise localization, and better disease monitoring, leading to improved treatment planning. The integration of hybrid imaging systems and novel radiotracers is further broadening clinical applications, making nuclear medicine indispensable in modern diagnostics and increasing market demand.
• Growing Adoption of Targeted Radionuclide Therapy for Cancer Treatment: Targeted radionuclide therapy offers a promising approach for treating various cancers by delivering radiation directly to tumor cells, minimizing damage to healthy tissue. The development of new radiopharmaceuticals and increasing clinical trials are expanding therapeutic options. Rising cancer incidence rates and personalized treatment strategies are driving adoption, positioning radionuclide therapy as a key growth segment within nuclear medicine, with significant market expansion potential.
• Increasing Investment in Research and Development for New Radiopharmaceuticals: Continuous R&D efforts are leading to the discovery of novel radiotracers and therapeutic agents, broadening the scope of nuclear medicine. Investment from pharmaceutical companies and government agencies accelerates innovation, enabling the development of more effective, safer, and targeted diagnostic and therapeutic options. This focus on R&D is crucial for addressing unmet medical needs and sustaining long-term market growth.
• Rising Awareness and Regulatory Support for Nuclear Medicine Procedures: Enhanced awareness among healthcare professionals and patients about the benefits of nuclear medicine is boosting procedure adoption. Regulatory agencies are streamlining approval processes and establishing guidelines that facilitate market entry for new radiopharmaceuticals. Supportive policies and reimbursement frameworks are further encouraging clinical use, thereby expanding the market and fostering innovation in nuclear medicine applications.
• Increasing Use of Nuclear Medicine in Personalized Medicine and Precision Healthcare: The ability of nuclear medicine to provide molecular and functional insights supports personalized treatment approaches. Tailoring therapies based on individual patient profiles improves efficacy and reduces side effects. The integration of nuclear medicine with genomics and other diagnostic modalities is advancing precision healthcare, creating new opportunities for market growth and positioning nuclear medicine as a cornerstone of individualized patient management.

The overall impact of these growth opportunities is set to significantly expand the nuclear medicine market, enhancing diagnostic and therapeutic capabilities, improving patient outcomes, and fostering innovation. As technological, clinical, and regulatory landscapes evolve, the market is poised for sustained growth, attracting investments and collaborations that will shape the future of healthcare.

Nuclear Medicine Market Driver and Challenges

The nuclear medicine market is influenced by a variety of technological, economic, and regulatory factors that shape its growth and development. Advances in imaging technology and radiopharmaceuticals are driving innovation, while economic considerations such as healthcare spending and reimbursement policies impact market expansion. Regulatory frameworks ensure safety and efficacy but can also pose barriers to entry and innovation. Additionally, the increasing prevalence of chronic diseases and cancer globally fuels demand for diagnostic and therapeutic solutions. Navigating these complex drivers and challenges is essential for stakeholders aiming to capitalize on emerging opportunities and address potential obstacles within this dynamic industry.

The factors responsible for driving the nuclear medicine market include:-

• Technological Advancements: The continuous development of high-resolution imaging devices and novel radiopharmaceuticals enhances diagnostic accuracy and therapeutic efficacy. Innovations like PET/CT and SPECT/CT improve disease detection, leading to increased adoption. These technological improvements reduce procedure times and improve patient outcomes, encouraging healthcare providers to invest in advanced nuclear medicine solutions. As research progresses, the pipeline of new radiotracers expands, further fueling market growth and opening new clinical applications.
• Rising Prevalence of Chronic Diseases and Cancer: The global increase in cancer cases and chronic illnesses such as cardiovascular and neurological disorders significantly boosts demand for nuclear medicine procedures. These conditions require precise diagnosis and targeted treatment, which nuclear medicine provides effectively. As the burden of these diseases grows, healthcare systems are increasingly adopting nuclear medicine for early detection and management, thereby expanding the market. This trend is particularly prominent in emerging economies where healthcare infrastructure is improving.
• Regulatory Approvals and Support: Stringent regulatory frameworks ensure the safety and efficacy of nuclear medicine products, fostering trust among healthcare providers and patients. Regulatory agencies like the FDA and EMA facilitate the approval process for new radiopharmaceuticals, encouraging innovation. Supportive policies and funding for research and development also accelerate product commercialization. These regulatory measures help maintain high standards, reduce risks, and promote market stability, ultimately encouraging investment and adoption across healthcare settings.
• Growing Healthcare Infrastructure and Investment: Increasing healthcare expenditure and infrastructure development, especially in emerging markets, are vital drivers. Investments in modern imaging facilities and nuclear medicine departments enable wider access to advanced diagnostic and therapeutic options. Public and private sector funding supports the procurement of sophisticated equipment and training of personnel, expanding the reach of nuclear medicine services. This infrastructure growth not only improves patient access but also stimulates market growth by creating new opportunities for manufacturers and service providers.* Expanding Awareness and Acceptance: Growing awareness among healthcare professionals and patients about the benefits of nuclear medicine procedures is boosting adoption rates. Educational initiatives and clinical guidelines promote understanding of its advantages in early diagnosis and targeted therapy. Acceptance by clinicians as a standard diagnostic tool encourages routine use, while patient awareness about minimally invasive procedures enhances demand. This increased acceptance supports market expansion and encourages further innovation in the field.

The challenges facing the nuclear medicine market include:-

• Regulatory and Safety Concerns: The complex regulatory landscape for nuclear medicine products can delay approvals and increase costs for manufacturers. Ensuring safety in handling radioactive materials requires strict compliance with safety standards, which can be resource-intensive. Concerns about radiation exposure and potential misuse also pose barriers to widespread adoption. These regulatory hurdles can slow down innovation and limit market entry, especially in regions with less developed regulatory frameworks, impacting overall growth.
• High Costs and Reimbursement Issues: The high cost of advanced imaging equipment and radiopharmaceuticals limits accessibility, particularly in low- and middle-income countries. Reimbursement policies vary significantly across regions, affecting the financial viability of providers. Lack of adequate reimbursement discourages healthcare facilities from investing in nuclear medicine, thereby restricting patient access. Cost-related barriers hinder market expansion and slow the adoption of new technologies, emphasizing the need for policy reforms to improve affordability.
• Short Half-life of Radiopharmaceuticals: Many radiotracers used in nuclear medicine have short half-lives, which complicates manufacturing, storage, and transportation. This logistical challenge limits the geographic reach of certain products and increases costs due to the need for nearby production facilities. It also restricts the availability of some innovative radiopharmaceuticals in remote or underserved areas, impacting patient access and market growth. Overcoming these limitations requires advancements in radiotracer stability and distribution infrastructure.

In summary, the nuclear medicine market is driven by technological innovations, increasing disease prevalence, supportive regulations, infrastructure development, and rising awareness. However, challenges such as regulatory complexities, high costs, reimbursement issues, and logistical constraints pose significant hurdles. These factors collectively influence the pace and scope of market growth, requiring strategic efforts from industry stakeholders to maximize opportunities while addressing obstacles. The overall impact is a dynamic landscape with substantial potential for expansion, provided that these challenges are effectively managed.

List of Nuclear Medicine Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies nuclear medicine companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the nuclear medicine companies profiled in this report include-

• Cardinal Health
• GE Healthcare
• Jubilant Pharma
• Novartis
• Curium Pharma
• SIEMENS
• Lantheus
• Bracco Imaging
• Bayer
• Eli Lilly

Nuclear Medicine Market by Segment

The study includes a forecast for the global nuclear medicine market by type, application, and region.

Nuclear Medicine Market by Type [Value from 2019 to 2035]:

• Diagnostic Nuclear Medicine
• Therapeutic Nuclear Medicine

Nuclear Medicine Market by Application [Value from 2019 to 2035]:

• Oncology
• Thyroid
• Cardiology
• Others

Nuclear Medicine Market by Region [Value from 2019 to 2035]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Nuclear Medicine Market

The nuclear medicine market has experienced significant growth driven by technological advancements, increasing prevalence of chronic diseases, and expanding applications in diagnostics and therapy. Countries are investing in research, infrastructure, and regulatory frameworks to enhance their capabilities. The United States leads in innovation and market size, while China and India are rapidly expanding due to rising healthcare demands. Germany and Japan are focusing on integrating advanced imaging techniques and personalized medicine approaches. These developments reflect a global shift towards more precise, effective, and minimally invasive diagnostic and treatment options, shaping the future landscape of nuclear medicine.

• United States: The US market is characterized by technological innovation, with significant investments in PET and SPECT imaging systems. Growing adoption of theragnostic and personalized medicine is boosting demand. Regulatory approvals for new radiopharmaceuticals are accelerating, and key players are expanding manufacturing capacities. The US also emphasizes research collaborations and clinical trials to advance nuclear medicine applications.
• China: China is experiencing rapid growth driven by increasing healthcare infrastructure and government initiatives to develop nuclear medicine. The country is investing heavily in new radiopharmaceutical production facilities and training programs. The adoption of advanced imaging modalities like PET/CT is rising, and domestic companies are gaining prominence through innovation and strategic partnerships.
• Germany: Germany focuses on integrating advanced imaging technologies such as hybrid PET/MRI systems and developing novel radiopharmaceuticals. The country emphasizes research and development, supported by strong regulatory frameworks. Germany also leads in clinical trials and academic research, contributing to global advancements in nuclear medicine.
• India: India is witnessing expanding nuclear medicine services due to rising chronic disease prevalence and healthcare access improvements. The market is driven by increasing adoption of PET/CT scans and the development of affordable radiopharmaceuticals. Government initiatives and private sector investments are enhancing infrastructure and training, fostering growth in both diagnostics and therapeutic applications.
• Japan: Japan emphasizes innovation in nuclear medicine, particularly in personalized and targeted therapies. The country is investing in advanced imaging technologies and radiopharmaceutical research. Japan's focus on aging populations and cancer treatment is propelling market growth, with collaborations between academia and industry facilitating new product development and clinical applications.

Features of the Global Nuclear Medicine Market

• Market Size Estimates: Nuclear medicine market size estimation in terms of value ($B).
• Trend and Forecast Analysis: Market trends (2019 to 2025) and forecast (2026 to 2035) by various segments and regions.
• Segmentation Analysis: Nuclear medicine market size by type, application, and region in terms of value ($B).
• Regional Analysis: Nuclear medicine market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
• Growth Opportunities: Analysis of growth opportunities in different types, applications, and regions for the nuclear medicine market.
• Strategic Analysis: This includes M&A, new product development, and competitive landscape of the nuclear medicine market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the nuclear medicine market by type (diagnostic nuclear medicine and therapeutic nuclear medicine), application (oncology, thyroid, cardiology, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 7 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Market Overview

• 2.1 Background and Classifications
• 2.2 Supply Chain

3. Market Trends & Forecast Analysis

• 3.1 Macroeconomic Trends and Forecasts
• 3.2 Industry Drivers and Challenges
• 3.3 PESTLE Analysis
• 3.4 Patent Analysis
• 3.5 Regulatory Environment

4. Global Nuclear Medicine Market by Type

• 4.1 Overview
• 4.2 Attractiveness Analysis by Type
• 4.3 Diagnostic Nuclear Medicine : Trends and Forecast (2019-2035)
• 4.4 Therapeutic Nuclear Medicine : Trends and Forecast (2019-2035)

5. Global Nuclear Medicine Market by Application

• 5.1 Overview
• 5.2 Attractiveness Analysis by Application
• 5.3 Oncology : Trends and Forecast (2019-2035)
• 5.4 Thyroid : Trends and Forecast (2019-2035)
• 5.5 Cardiology : Trends and Forecast (2019-2035)
• 5.6 Others : Trends and Forecast (2019-2035)

6. Regional Analysis

• 6.1 Overview
• 6.2 Global Nuclear Medicine Market by Region

7. North American Nuclear Medicine Market

• 7.1 Overview
• 7.2 North American Nuclear Medicine Market by Type
• 7.3 North American Nuclear Medicine Market by Application
• 7.4 The United States Nuclear Medicine Market
• 7.5 Canadian Nuclear Medicine Market
• 7.6 Mexican Nuclear Medicine Market

8. European Nuclear Medicine Market

• 8.1 Overview
• 8.2 European Nuclear Medicine Market by Type
• 8.3 European Nuclear Medicine Market by Application
• 8.4 German Nuclear Medicine Market
• 8.5 French Nuclear Medicine Market
• 8.6 Italian Nuclear Medicine Market
• 8.7 Spanish Nuclear Medicine Market
• 8.8 The United Kingdom Nuclear Medicine Market

9. APAC Nuclear Medicine Market

• 9.1 Overview
• 9.2 APAC Nuclear Medicine Market by Type
• 9.3 APAC Nuclear Medicine Market by Application
• 9.4 Chinese Nuclear Medicine Market
• 9.5 Indian Nuclear Medicine Market
• 9.6 Japanese Nuclear Medicine Market
• 9.7 South Korean Nuclear Medicine Market
• 9.8 Indonesian Nuclear Medicine Market

10. ROW Nuclear Medicine Market

• 10.1 Overview
• 10.2 ROW Nuclear Medicine Market by Type
• 10.3 ROW Nuclear Medicine Market by Application
• 10.4 Middle Eastern Nuclear Medicine Market
• 10.5 South American Nuclear Medicine Market
• 10.6 African Nuclear Medicine Market

11. Competitor Analysis

• 11.1 Product Portfolio Analysis
• 11.2 Operational Integration
• 11.3 Porter's Five Forces Analysis
  • Competitive Rivalry
  • Bargaining Power of Buyers
  • Bargaining Power of Suppliers
  • Threat of Substitutes
  • Threat of New Entrants
• 11.4 Market Share Analysis

12. Opportunities & Strategic Analysis

• 12.1 Value Chain Analysis
• 12.2 Growth Opportunity Analysis
  • 12.2.1 Growth Opportunity by Type
  • 12.2.2 Growth Opportunity by Application
• 12.3 Emerging Trends in the Global Nuclear Medicine Market
• 12.4 Strategic Analysis
  • 12.4.1 New Product Development
  • 12.4.2 Certification and Licensing
  • 12.4.3 Mergers, Acquisitions, Agreements, Collaborations, and Joint Ventures

13. Company Profiles of the Leading Players Across the Value Chain

• 13.1 Competitive Analysis Overview
• 13.2 Cardinal Health
  • Company Overview
  • Nuclear Medicine Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.3 GE Healthcare
  • Company Overview
  • Nuclear Medicine Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.4 Jubilant Pharma
  • Company Overview
  • Nuclear Medicine Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.5 Novartis
  • Company Overview
  • Nuclear Medicine Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.6 Curium Pharma
  • Company Overview
  • Nuclear Medicine Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.7 SIEMENS
  • Company Overview
  • Nuclear Medicine Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.8 Lantheus
  • Company Overview
  • Nuclear Medicine Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.9 Bracco Imaging
  • Company Overview
  • Nuclear Medicine Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.10 Bayer
  • Company Overview
  • Nuclear Medicine Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.11 Eli Lilly
  • Company Overview
  • Nuclear Medicine Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing

14. Appendix

• 14.1 List of Figures
• 14.2 List of Tables
• 14.3 Research Methodology
• 14.4 Disclaimer
• 14.5 Copyright
• 14.6 Abbreviations and Technical Units
• 14.7 About Us
• 14.8 Contact Us